Neurolixis is a science-driven company and places high priority on characterizing its drug development candidates (NLX-112 and NLX-101) in rigorously-conducted pharmacological studies. The results from these studies are reported in reputable international peer-reviewed neuroscience and pharmacology journals.
Note: NLX-112 was previously known as F13640 (befiradol) and NLX-101 was previously known as F15599.
For abstracts of key publications (and some free PDFs of the full articles) see the links below.
Selected Publications on NLX-112:
The novel 5-HT1A receptor agonist, NLX-112, reduces L-DOPA-induced abnormal involuntary movements in rat: a chronic administration study with microdialysis measurements.
McCreary AC, Varney MA, Newman-Tancredi A
Neuropharmacology. 2016 Jan 8. pii: S0028-3908(16)30013-2. doi: 10.1016/j.neuropharm.2016.01.013.
NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat.
Iderberg H, McCreary AC, Varney MA, Kleven MS, Koek W, Bardin L, Depoortère R, Cenci MA, Newman-Tancredi A
Exp Neurol. 2015 May 30. doi: 10.1016/j.expneurol.2015.05.021
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and post-synaptic 5-HT1A receptors in the rat.
Lladò-Pelfort L, Assié MB, Newman-Tancredi A, Artigas F, Celada P.
Psychopharmacology (Berl). 2012 May;221(2):261-72. Epub 2011 Dec 3.
Dual hyperalgesic and analgesic effects of the high-efficacy 5-HT1A agonist F13640: relationship with receptor occupancy and kinetic parameters.
Selected Publications on NLX-101:
Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: a pharmacoMRI study (free PDF).
Pinpointing brain stem mechanisms responsible for autonomic dysfunction in Rett syndrome: therapeutic perspectives for 5-HT1A agonists
Levitt ES, Hunnicutt BJ, Knopp SJ, Williams JT, Bissonnette JM.
J Appl Physiol (1985). 2013 Dec;115(11):1626-33. Epub 2013 Oct 3.
Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist.
Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors.
F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists.
Depoortère R, Auclair AL, Bardin L, Colpaert FC, Vacher B, Newman-Tancredi A.,
Eur Neuropsychopharmacol. 2010 Sep;20(9):641-54.
Biased agonism at serotonin 5-HT1A receptors: preferential postsynaptic activity for improved therapy of CNS disorders.
Neuropsychiatry, April 2011, Vol. 1, No. 2, Pages 149-164.